Literature DB >> 21455869

Radiofrequency ablation for the endoscopic eradication of esophageal squamous high grade intraepithelial neoplasia and mucosal squamous cell carcinoma.

F G van Vilsteren1, L Alvarez Herrero, R E Pouw, F J ten Kate, M Visser, C A Seldenrijk, M I van Berge Henegouwen, B L Weusten, J J Bergman.   

Abstract

BACKGROUND AND STUDY AIMS: Radiofrequency ablation (RFA) with or without prior endoscopic resection safely and effectively removes early neoplasia in Barrett's esophagus. We speculated that this approach might also be suited for early squamous neoplasia of the esophagus. The aim of the study was to assess our initial experiences with RFA for high grade intraepithelial neoplasia (HGIN) and esophageal squamous cell cancer (ESCC) limited to the mucosa. PATIENTS AND METHODS: This was a prospective case series study in two tertiary centers. Patients with at least one unstained lesion (USL) of the esophagus using Lugol's chromoendoscopy and squamous HGIN/ESCC upon biopsy were included. In the case of nonflat USLs, endoscopic resection was performed for staging and to render the mucosa flat. After endoscopic resection and subsequent circumferential RFA, chromoendoscopy was repeated every 3 months with focal RFA of residual USLs. Follow-up chromoendoscopy was repeated at 6 months and annually thereafter. The main outcome measure was complete histological response for any squamous intraepithelial neoplasia or ESCC.
RESULTS: A total of 13 patients (10 HGIN, three ESCC) were included. Following endoscopic resection in nine patients, the median extent of USLs was 4 cm and 50 % of circumference. All 13 patients achieved a complete response after a median of 2 RFA sessions (IQR 1 - 3 sessions). RFA-related complications included two mucosal lacerations (at the endoscopic resection scar) and one intramural hematoma, none requiring therapy. Endoscopic resection-/RFA-related complications were three stenoses. Dilation resulted in perforation in one patient (managed with a covered stent). There were no recurrences (median follow-up 17 months [IQR 11 - 22 months]).
CONCLUSIONS: This study suggests that RFA with or without prior endoscopic resection for esophageal squamous HGIN and mucosal ESCC is feasible and effective. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2011        PMID: 21455869     DOI: 10.1055/s-0030-1256309

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  16 in total

Review 1.  Emerging indications of endoscopic radiofrequency ablation.

Authors:  Aymeric Becq; Marine Camus; Gabriel Rahmi; Vincent de Parades; Philippe Marteau; Xavier Dray
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

2.  Endoscopic radiofrequency ablation for early esophageal squamous cell neoplasia: report of safety and effectiveness from a large prospective trial.

Authors:  Shun He; Jacques Bergman; Yueming Zhang; Bas Weusten; Liyan Xue; Xiumin Qin; Lizhou Dou; Yong Liu; David Fleischer; Ning Lu; Sanford M Dawsey; Gui-Qi Wang
Journal:  Endoscopy       Date:  2015-02-10       Impact factor: 10.093

Review 3.  Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.

Authors:  Nathan A Gray; Robert D Odze; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2011-08-09       Impact factor: 10.864

4.  Is it justified to ablate flat-type esophageal squamous cancer? An analysis of endoscopic submucosal dissection specimens of lesions meeting the selection criteria of radiofrequency studies.

Authors:  Marnix Jansen; Dirk W Schölvinck; Ryoji Kushima; Shigeki Sekine; Bas L A M Weusten; Guiqi Q Wang; David E Fleischer; Shigetaka Yoshinaga; Sanford M Dawsey; Sybren L Meijer; Jacques J G H M Bergman; Ichiro Oda
Journal:  Gastrointest Endosc       Date:  2014-12       Impact factor: 9.427

5.  Prospective study of endoscopic focal cryoballoon ablation for esophageal squamous cell neoplasia in China.

Authors:  Yan Ke; Sanne N van Munster; Liyan Xue; Shun He; Yueming Zhang; Lizhou Dou; Yong Liu; Xudong Liu; Yumeng Liu; Wei Li; Ning Lv; Sanford M Dawsey; Bas L A M Weusten; Jacques J G H M Bergman; Guiqi Wang
Journal:  Gastrointest Endosc       Date:  2019-03-25       Impact factor: 9.427

Review 6.  High-grade dysplasia and intramucosal adenocarcinoma in Barrett's esophagus: the role of endoscopic eradication therapy.

Authors:  Cadman L Leggett; Ganapathy A Prasad
Journal:  Curr Opin Gastroenterol       Date:  2012-07       Impact factor: 3.287

7.  Durability of radiofrequency ablation for treatment of esophageal squamous cell neoplasia: 5-year follow-up of a treated cohort in China.

Authors:  Xinying Yu; Sanne N van Munster; Yueming Zhang; Liyan Xue; David E Fleischer; Bas L A M Weusten; Ning Lu; Sanford S M Dawsey; Jacques J G H M Bergman; Guiqi Wang
Journal:  Gastrointest Endosc       Date:  2018-10-26       Impact factor: 9.427

8.  A case of esophageal squamous cell intraepithelial neoplasia with positivity for type 16 human papillomavirus successfully treated with radiofrequency ablation.

Authors:  Alessandro Repici; Chiara Genco; Andrea Anderloni; Paola Spaggiari; Rossana Mineri; Rosanna Minieri; Alessandra Carlino; Manol Jovani; Vincenzo Villanacci; Prateek Sharma; Alberto Malesci
Journal:  J Gastrointest Oncol       Date:  2014-04

9.  Prospective feasibility study on the use of multiband mucosectomy for endoscopic resection of early squamous neoplasia in the esophagus.

Authors:  Y M Zhang; D F Boerwinkel; S He; B L A M Weusten; L Y Xue; D E Fleischer; N Lu; S M Dawsey; S M Zuo; X M Qin; L Z Dou; J J G H M Bergman; G Q Wang
Journal:  Endoscopy       Date:  2012-12-20       Impact factor: 10.093

10.  Predictors for postoperative esophageal stricture after balloon-based radiofrequency ablation for early esophageal squamous neoplasia: a multicenter validation study.

Authors:  Wen-Lun Wang; I-Wei Chang; Chien-Chuan Chen; Wei-Lun Chang; Yin-Yi Chu; Ping-Hsiu Wu; Wei-Chen Tai; Po-Yueh Chen; Ping-Hsin Hsieh; Chen-Shuan Chung; Chi-Yang Chang; Jaw-Town Lin; Hsiu-Po Wang; Ching-Tai Lee
Journal:  Therap Adv Gastroenterol       Date:  2016-02-25       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.